Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial

Clinical trial NCT06919380 · RECRUITING

Trial details

NCT number: NCT06919380
Sponsor: Li Shiyue
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Anti-MDA5 Positive Dermatomyositis-Associated RP-ILD Rapidly Progressive Interstitial Lung Disease

Start date: 2025-04-15
Primary completion: 2026-12-31
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.